---
title: "Atricure Still Faces Broad, Evolving Risks Despite No Material Changes in 2025 10-K Disclosures"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294017350.md"
description: "Atricure, Inc. (ATRC) disclosed a new risk under the Regulation category in its 2025 Form 10-K. Despite no material changes to previously outlined risk factors, the company remains exposed to broad risks that could materially impact its business and financial results. Unknown or currently immaterial risks may also emerge. Wall Street maintains a Moderate Buy consensus on ATRC stock, based on five buy ratings and two holds."
datetime: "2026-07-28T06:00:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294017350.md)
  - [en](https://longbridge.com/en/news/294017350.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294017350.md)
---

# Atricure Still Faces Broad, Evolving Risks Despite No Material Changes in 2025 10-K Disclosures

Atricure, Inc. (ATRC) has disclosed a new risk, in the Regulation category.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

The analyst notes that Atricure, Inc. remains exposed to the broad set of risks previously outlined in its Form 10-K for the year ended December 31, 2025, any of which could materially impact its business, financial position or future results. He also observes that unknown or currently immaterial risks may still emerge and adversely affect Atricure’s operations, despite no material changes in disclosed risk factors.

Overall, Wall Street has a Moderate Buy consensus rating on ATRC stock based on 5 Buys and 2 Holds.

To learn more about Atricure, Inc.’s risk factors, click here.

### Related Stocks

- [ATRC.US](https://longbridge.com/en/quote/ATRC.US.md)

## Related News & Research

- [AtriCure Chief Scientific Officer Vinayak Doraiswamy disposes of $233,280 in common shares](https://longbridge.com/en/news/294417197.md)
- [AtriCure Q2 net income turns to USD 8.96 million; revenue rises 12.8% to USD 153.6 million year over year](https://longbridge.com/en/news/293959967.md)
- [GrafTech International Signals Stable Risk Profile with No Material Changes in 2026 Form 10-K](https://longbridge.com/en/news/293814726.md)
- [Curbline Properties Corp. Risk Profile Unchanged: Existing 10-K Disclosures Remain Key for Investors](https://longbridge.com/en/news/294317583.md)
- [Teledyne Confirms No New Risk Factors in 2025 10-K, Urges Investors to Review Existing Disclosures](https://longbridge.com/en/news/293836913.md)